FI105348B - Menetelmä proteiinien käsittelemiseksi endoproteolyyttisesti sekä menetelmä proteiinien valmistamiseksi (mikro)biologisesti - Google Patents

Menetelmä proteiinien käsittelemiseksi endoproteolyyttisesti sekä menetelmä proteiinien valmistamiseksi (mikro)biologisesti Download PDF

Info

Publication number
FI105348B
FI105348B FI921847A FI921847A FI105348B FI 105348 B FI105348 B FI 105348B FI 921847 A FI921847 A FI 921847A FI 921847 A FI921847 A FI 921847A FI 105348 B FI105348 B FI 105348B
Authority
FI
Finland
Prior art keywords
furin
protein
enzyme
treatment
cells
Prior art date
Application number
FI921847A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI921847L (fi
FI921847A0 (fi
Inventor
De Ven Willem Jan Marie Van
Den Ouweland Anna Maria Wi Van
Duijnhoven Johannes Lamber Van
Antonius Johannes Mar Roebroek
Piet Nico Maria Koning
Original Assignee
Univ Leuven Kath
De Ven Willem Jan Marie Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26646599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105348(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8902651A external-priority patent/NL8902651A/nl
Application filed by Univ Leuven Kath, De Ven Willem Jan Marie Van filed Critical Univ Leuven Kath
Publication of FI921847L publication Critical patent/FI921847L/fi
Publication of FI921847A0 publication Critical patent/FI921847A0/fi
Application granted granted Critical
Publication of FI105348B publication Critical patent/FI105348B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI921847A 1989-10-25 1992-04-24 Menetelmä proteiinien käsittelemiseksi endoproteolyyttisesti sekä menetelmä proteiinien valmistamiseksi (mikro)biologisesti FI105348B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NL8902651 1989-10-25
NL8902651A NL8902651A (nl) 1989-10-25 1989-10-25 Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van eiwitten.
NL9000917 1990-04-18
NL9000917A NL9000917A (nl) 1989-10-25 1990-04-18 Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
PCT/NL1990/000151 WO1991006314A2 (en) 1989-10-25 1990-10-12 Pharmaceutical composition having an endoproteolytic activity; a process for endoproteolytically processing (precursor) proteins and for the (micro)biological production of proteins
NL9000151 1990-10-12

Publications (3)

Publication Number Publication Date
FI921847L FI921847L (fi) 1992-04-24
FI921847A0 FI921847A0 (fi) 1992-04-24
FI105348B true FI105348B (fi) 2000-07-31

Family

ID=26646599

Family Applications (1)

Application Number Title Priority Date Filing Date
FI921847A FI105348B (fi) 1989-10-25 1992-04-24 Menetelmä proteiinien käsittelemiseksi endoproteolyyttisesti sekä menetelmä proteiinien valmistamiseksi (mikro)biologisesti

Country Status (13)

Country Link
US (1) US5989856A (da)
EP (3) EP0693286A1 (da)
JP (2) JP3191111B2 (da)
AT (1) ATE147437T1 (da)
AU (1) AU6613290A (da)
CA (1) CA2069929C (da)
DE (1) DE69029663T3 (da)
DK (1) DK0497828T4 (da)
ES (1) ES2099714T5 (da)
FI (1) FI105348B (da)
GR (1) GR3023013T3 (da)
NL (1) NL9000917A (da)
WO (1) WO1991006314A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935815A (en) * 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
DK52293D0 (da) * 1993-05-05 1993-05-05 Novo Nordisk As
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
US6596526B1 (en) 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
EP1756275A1 (en) * 2004-04-23 2007-02-28 Novozymes A/S Method for obtaining mature protease by enzymatic digestion
WO2008141824A2 (en) * 2007-05-22 2008-11-27 Baxter International Inc. Preparative purification process for human furin
SI2235197T1 (sl) 2007-12-27 2017-10-30 Baxalta GmbH Procesi celične kulture
MX2010007344A (es) 2007-12-31 2010-11-09 Baxter Int Furina recombinante substancialmente libre de proteina animal y metodos para la produccion de la misma.
US20130149295A1 (en) 2010-05-12 2013-06-13 Martine Cohen-Solal Furin and biologically active derivatives thereof for use in the prevention or treatment of an inflammatory disease
SG10201604488TA (en) 2011-06-02 2016-07-28 Baxter Int Formulations Of Recombinant Furin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells

Also Published As

Publication number Publication date
DK0497828T4 (da) 2008-02-04
JP3191111B2 (ja) 2001-07-23
ES2099714T3 (es) 1997-06-01
DK0497828T3 (da) 1997-07-07
JPH05504051A (ja) 1993-07-01
JP2001238683A (ja) 2001-09-04
DE69029663D1 (de) 1997-02-20
EP0693286A1 (en) 1996-01-24
FI921847L (fi) 1992-04-24
EP0885956A1 (en) 1998-12-23
AU6613290A (en) 1991-05-31
FI921847A0 (fi) 1992-04-24
EP0497828A1 (en) 1992-08-12
CA2069929A1 (en) 1991-04-26
GR3023013T3 (en) 1997-07-30
WO1991006314A2 (en) 1991-05-16
WO1991006314A3 (en) 1991-09-05
EP0497828B1 (en) 1997-01-08
US5989856A (en) 1999-11-23
CA2069929C (en) 2002-08-27
EP0497828B2 (en) 2007-10-03
DE69029663T2 (de) 1997-09-04
ES2099714T5 (es) 2008-04-01
JP3270760B2 (ja) 2002-04-02
NL9000917A (nl) 1991-05-16
ATE147437T1 (de) 1997-01-15
DE69029663T3 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
JP2525438B2 (ja) ファクタ―８：ｃの製造方法
KR920007666B1 (ko) 변형된 섬유소 용해제의 제조방법
US6274365B1 (en) Pharmaceutical composition having an endoproteolytic activity
FI105348B (fi) Menetelmä proteiinien käsittelemiseksi endoproteolyyttisesti sekä menetelmä proteiinien valmistamiseksi (mikro)biologisesti
JP2002514887A (ja) トロンボポイエチンポリペプチドの分泌方法
JP2001504324A (ja) α―ガラクトシダーゼＡ欠損症の治療
JPH01502080A (ja) 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
JP2641875B2 (ja) ハイブリッドタンパク質
JPH07501703A (ja) プロホルモンコンバターゼで形質転換された細胞およびポリペプチド合成
RU2128705C1 (ru) Протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов млекопитающих, рекомбинантный протеин, ингибирующий вызываемую коллагеном агрегацию тромбоцитов, фрагмент днк, кодирующий рекомбинантный протеин, вектор экспрессии (варианты), штамм культивируемых животных клеток внк - продуцент рекомбинантного протеина (варианты), способ получения рекомбинантного протеина, фармацевтическая композиция
KR20240110541A (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
WO1989012685A1 (en) Improved protein c molecules and method for making and activating same
JP2872255B2 (ja) ファクター▲ｖｉｉｉ▼の高収量生産法
JPH10262668A (ja) 血管形成誘導因子をコードするタンパク質コード配列を包含するｄｎａ配列
EP0271003A2 (en) Expression vectors
JP3045307B2 (ja) 活性化プロテインｃを生成するための細胞培養法
CN104926946A (zh) 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
Ribó et al. Production of Human Pancreatic Ribonuclease inSaccharomyces cerevisiaeandEscherichia coli
NO311895B1 (no) Anvendelse av furin eller furinlignende enzym for spalting av et protein, fremgangsmåte for mikrobiologisk fremstilling av etprotein og pattedyrcelle som omfatter DNA som koder for enzymet
BG60507B2 (bg) Човешки тъканен плазминогенен активатор
Mertvetsov Chemo-enzymatic synthesis of the human angiogenin gene. Construction of bacterial strains, producers of human angiogenin. Elaboration of a technology for the purification and preparation of angiogenin
JPWO1996003434A1 (ja) 巨核球分化増殖因子
BG60509B2 (bg) Човешки тъканен плазминогенен активатор
AU2262688A (en) Improved protein c molecules and method for making and activating same

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN

GB Transfer or assigment of application

Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN